AI as a Biomarker for ABRS in Patients With HCC

Julien Calderaro, MD, PhD, discusses his latest research published in The Lancet Oncology investigating if AI can serve as a biomarker of sensitivity to atezolizumab plus bevacizumab in patients with HCC.

Prior research has shown that when evaluated using molecular biology profiling techniques, the atezolizumab–bevacizumab response signature demonstrated a connection with progression-free survival following the start of treatment.

Dr. Calderaro highlights the potential of AI to predict ABRS expression, explains how the AI model was trained, and details the study’s larger implications.